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A radiolabeled protein composition adapted for radia­
tion therapy which comprises a radioisotope and a pro­
tein material containing about 6 or more percent amino 
acids which have a sulfhydryl-containing side chain. A 
method for carrying out radiation synovectomy of ar­
thritic joints. Rhenium radiolabeled protein micro- 
spheres are administered  which contain cysteine and 
other am ino acids. A method for radiolabeling a protein 
composition whereby the composition is treated with a 
reducing agent capable of reducing disulfides to sulfhy- 
dryls prior to radiolabeling.
22 Claims, 8 Drawing Sheets
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FIG 3
RADIOACTIVITY DISTRIBUTION IN RABBIT URINE WITHIN 4 DAYS
POLYCYSTEINE-POLYLYSINE{1:1) MICROSPHERES 
USED: 6-80 jjm(MAINLY 15-25 \im)
0
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FIG 4
RETENTION OF RADIOACTIVITY AT 96 HOURS
POLYCYSTE!NE-POLYLYSINE(1:1) MICROSPHERES 
USED: 6-80 pm(MA!NLY 15-25 \im)
■  RABBIT A 
i  RABBIT B 
|  RABBIT C 
B  RABBIT D
TISSUErCARCASE 
(EXCEPT STIFLE and URINE) 
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FIGS
TISSUE BIODISTRIBUTION AT 96 HOURS
POLYCYSTEINE-LYSINE(1:1) MICROSPHERES USED: 
6-80 [jm(MAINLY 15-25 pm)
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FIG 6
LEACHING TEST OF Re-186 LABELED MICROSPHERES 
1:1 POLYCYSTEINE AND POLYLYSINE
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FIG 7
RETENTION OF RADIOACTIVITY AT 24 HOURS
MICROSPHERES USED: 1 -50 pm (No. 1,2)
23 pm (No. 3)
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FIG 8
TISSUE BIODISTRIBUTION AT 24 HOURS
Liver Kidney Lung Spleen Heart Muscle Blood
RABBIT ORGANS
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RADIOLABELED PROTEIN COMPOSITION AND 
METHOD FOR RADIATION SYNOVECTOMY
10
15
BACKGROUND OF THE INVENTION
This invention relates to radiolabeled protein compo­
sitions being adaptable for radiation therapy, diagnosis 
and research. The invention also relates to a method of 
using protein microspheres for radiation synovectomy.
It is estimated that 1-3% of the population in the 
United States has rheumatoid arthritis (hereinafter RA), 
which can cause chronic synovial inflammation and can 
lead to progressive loss of joint function and significant 
disability. RA has heretofore been treated primarily by 
surgical or chemical synovectomy. Surgical synovec­
tomy consists of the surgical removal of the inflamed 
lining of the joint (synovium), and in general can be 
expected to provide limited periods of symptomatic 
relief. It is technically difficult, however, to completely 20 
remove the synovium from the joint. Surgical synovec­
tomy entails risks such as infection, hemorrhage and 
anesthetic problems. Surgery often requires prolonged 
periods of hospitalization and rehabilitation for recov­
ery. Surgery is expensive, invasive and is not attractive 25 
for repeat treatments. Proposed methods of chemical 
synovectomy use osmic acid, cobra venom or other 
agents and often have significant systemic effects such 
as injury to the articular cartilage.Radiation synovectomy has been proposed, for exam­
ple, by Johnson et al., Absorbed Dose Profiles for Radio­
nuclides o f Frequent use in Radiation Synovectomy, Ar­
thritis and Rheumatism, Vol. 34, No. 12, p. 1521 (Dec. 
1991), for the treatment of RA and offers a viable alter­
native to surgery and chemical synovectomy. Radioiso­
topes are commonly used for research, treatment and 
diagnosis in the field of nuclear medicine. Such applica­
tions include liver, lung, bone and tumor scanning and 
radiotherapy. Radiation synovectomy radiotherapy 
involves delivering a lethal dose of beta radiation to 
diseased synovial membrane.Radiation synovectomy has been used in Europe but 
certain disadvantages have made it generally unaccept­
able for use in the United States. Radiation synovec- 45 
tomy treatments in Europ>e have employed yttnum-90 
radiocolloids which emit beta radiation but do not emit 
gamma radiation. It has therefore not been possible to 
track radiation leakage and the spread of radioactivity 
within the patient using an external gamma ray detec­
tor. Additionally, prior methods of radiation synovec­
tomy often suffer from high radioactivity leakage rates 
of the particulate preparations which serve as carriers 
for the radioactivity. Radiation synovectomy treat­
ments have therefore lacked the ideal source of radia­
tion and the ideal radioactivity carrier.
Microspheres formed from human serum albumin 
have been proposed for use as radioactivity carriers in 
connection with the use of radioactivity for diagnostic 
purposes, e.g., lung scanning, as in Radiopharmaceuti­
cals, Soc’y Nuc. Med., p. 282, New York (1980). Specif­
ically, human serum albumin microspheres have been 
radiolabeled with Tc-99m and injected or otherwise 
allowed to enter a mammalian host. A gamma ray de­
tector has then been used to image certain areas of the 65 
patient. Microspheres labeled with Tc-99m, however, 
are not suitable for radiation therapy, and radiation 







emits gamma radiation, not the beta radiation which is 
lethal to diseased synovial membrane.
Accordingly, a need has existed for an improved 
method and materials, including radioisotope carrier, 
for use in radiation synovectomy treatment of RA. A 
need has also existed for an improved radioisotope car­
rier for use in research, treatment and diagnosis in the 
field of nuclear medicine.
SUMMARY OF THE INVENTION
Among the several objects of the invention, there­
fore, are the provision of an improved method for treat­
ing RA which is relatively free of harmful side effects 
and the provision of an improved radioactivity carrier 
which is adaptable for use in a wide variety of diagnos­
tic, treatment and research applications in the field of 
nuclear medicine. Other objects and features of the 
invention will be in part apparent and in part pointed 
out hereinafter.
Briefly, therefore, the invention is directed to a radi­
olabeled protein composition adapted for radiation ther­
apy or diagnosis of a mammal which comprises a beta 
radiation emitting radioisotope and a protein material 
containing at least 6 molar percent amino acids residues 
having a sulfhydryl-containing side chain.
The invention is further directed to a substantially 
spherical radiolabeled protein microsphere adapted for 
radiation therapy of a mammal comprising a radioiso­
tope selected from the group consisting of Re-186, Re- 
188 and the combination of Re-186 and Re-188, and 
protein material containing at least about 25 molar per­
cent cysteine and at least about 25 molar percent amino 
acids having a nitrogen-containing side chain.
The invention is further directed to a substantially 
spherical radiolabeled microsphere adapted for radia­
tion therapy of a mammal consisting essentially of a 
radioisotope selected from the group consisting of Re- 
186, Re-188 and the combination of Re-186 and Re-188, 
and protein material containing at least about 35 molar 
percent lysine and at least about 35 molar percent cyste­
ine.The invention is further directed to a method for 
carrying out radiation synovectomy of arthritic joints, 
comprising administering to a mammal affected with an 
arthritic joint substantially spherical microspheres com­
prising a protein material containing cysteine, said mi­
crospheres being radiolabeled with a beta radiation 
emitting radioisotope selected from the group consist­
ing of Re-186, Re-188 and the combination of Re-186 
and Re-188.The invention is further directed to an improvement 
in a method for radiolabeling a protein composition 
containing amino acids having a sulfhydryl-containing 
side chain for use in radiotherapy and diagnosis in mam­
mals. The improvement comprises contacting the com­
position with a reducing agent capable of reducing 
disulfides to sulfhydryls and thereafter radiolabeling the 
composition.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a schematic of a method for radiolabeling 
protein microspheres.FIG. 2 is a schematic of a second method for radiola­
beling protein microspheres.
FIG. 3 is a plot of the radioactivity distribution in the 
urine of rabbits tested using the microspheres and 
method of the invention.
5,403,573
FIG. 4 is a plot of the radioactivity distribution in 
rabbits tested using the microspheres and method of the invention.
FIG. 5 is a plot of the radioactivity distribution in 
rabbits tested using the microspheres and method of the invention.
FIG. 6 is a plot of the results of leaching tests reflect­
ing the chemical durability of microspheres of the in­vention.
FIG. 7 is a plot of the radioactivity distribution in the 
urine of rabbits tested using the microspheres and method of the invention.
FIG. 8 is a plot of the radioactivity distribution in 
rabbits tested using the microspheres and method of the invention.
DETAILED DESCRIPTION OF THE 
INVENTION
“Protein compositions” as used herein designates 
both those compositions which comprise albumin and 
other proteins separated from blood products or other 
fluids from a mammal and those compositions which 
comprise chemically synthesized or microbially manu­
factured proteins. “Synthetic” as used herein in refer­
ence to proteins and microspheres means produced 
from materials other than human blood products. All 
percentages expressed herein are molar percent unless 
otherwise indicated.
It has been discovered that protein compositions 
radiolabeled with Re-186 or Re-188 are effective for 
radiotherapy. In particular it has been discovered that 
protein microspheres radiolabeled with Re-188 or Re- 
186 are effective for use in the treatment of rheumatoid 
arthritis (RA) by radiation synovectomy. It has also 
been discovered that microspheres comprising proteins 
having a predetermined minimum concentration of 
amino acid residues having sulfhydryl-containing side 
chains have advantages over previously known protein 
microspheres and other radioactivity carriers used in 
treatment, diagnosis and research in the field of nuclear medicine.
The composition and method of the invention in­
volve the use of rhenium as a source of radiation at­
tached to protein compositions. Re-186 and Re-188 emit 
gamma rays, and therefore provide the advantage of 
being detectable in the host’s system by detection meth­
ods known in the field of nuclear medicine including the 
sodium iodide method, germanium method or other 
known methods of gamma ray detection. Re-186 and 
Re-188 decay by /3-emission which provides the lethal 
dose necessary for radiotherapy. Re-186 decays into a 
stable daughter product and is characterized by a half- 
life of about 90 hours, a strong /3-emission (1.07 MeV), 
and an essentially monoenergetic 137 keV imageable 
gamma ray emission (9%). Re-188 decays into a stable 
daughter product and is characterized by a half-life of 
about 17 hours, a strong /3-emission (2.13 MeV), a 155 
keV imageable gamma-ray emission (15%).
Re-188 is preferred over Re-186 for certain applica­
tions such as radiation synovectomy because concerns 
relating to containment of radioactivity over time are 
not as great due to Re-188’s shorter half-life, i.e., the 
time period during which Re-188 leakage is potentially 
dangerous to the host is shorter. Additionally, Re-188’s 
higher beta energy provides the necessary penetration 
to treat large joints such as the human knee. Re-188 is 
also advantageously readily producible from a W- 188/Re-188 radioisotope generator analogous to known
3
Mo-99/Tc-99m generators and consequently can be 
readily generated on-site and provided as a “no carrier 
added” radioisotope. Both Re-186 and Re-188 are 
adaptable to radiolabeling by attachment thereof to 
protein compositions, as described hereinbelow.
The radiolabeled protein compositions of the inven­
tion may take various geometric forms including nonu­
niform globules, generally rectangular conformations, 
irregular conformations, or substantially spherical mi­
crospheres. Substantially spherical microspheres are 
preferred for radiation synovectomy for reasons includ­
ing their being more readily sizable, classifiable, and 
more resistant to fragmentation, than other conforma­
tions. As to sizability, there are ongoing studies and 
indications that microspheres of certain narrow size 
ranges of diameters such as, for example, 10 to 30 mi­
crons, may be most appropriate for synovectomy of a 
particular joint. It is advantageous, therefore, to be able 
to select microspheres from a predetermined range of 
diameters, if it is believed that a certain range of diame­
ters, or combination of ranges, is most appropriate for the particular application.
Three methods for producing protein microspheres 
radiolabeled with Re or other radioisotopes are 1) the 
formation of microspheres from radiolabeled material, 
2) incorporation of various radionuclides during the 
formation of microspheres and, preferably, 3) attach­
ment of radionuclides to preformed protein mir.ro- 
spheres. The preparation of protein microspheres for 
subsequent radiolabeling in accordance with the pre­ferred method involves emulsification or formation of a 
suspension of aqueous protein droplets in oil, gelation or 
solidification, by application of heat, of the aqueous 
protein droplets into rigid microspheres and separation 
and sizing of solidified microspheres. The preparation 
of HSA microspheres in this manner is known in the art 
and described in Radiopharmaceuticals, Soc’y Nuc. 
Med., pp. 282-83, New York (1980) and in White, Prop­
erties & Manufacturing Techniques o f Human Serum 
Albumin Microsphere, M. S. Cer. Eng. Thesis, U. of 
Mo.-Rolla, p.1-38 (991). This latter reference, at pages 
39-61, also describes an alternative method, the drop 
tube system, suitable for producing protein micro­
spheres of the invention. The method of making the 
protein microspheres is not in itself critical to the inven­
tion. Described below are examples illustrating specific methods for preparing protein microspheres.
The protein microspheres of the invention have a 
diameter of less than about 100 microns, preferably between about 3 and about 50 microns, more preferably 
between about 5 and about 30 microns, and most prefer­
ably between about 10 and about 20 microns. As dis­
cussed above, different sizes and size distributions of 
microspheres are desired for different applications. Re­
search is ongoing with respect to the relationship be­
tween microsphere size and efficacy for radiation ther­
apy, as measured by, for example, containment within 
the joint being treated. The density of the microspheres 
is generally close to the density of water, preferably 
between about 1.0 and about 1.05 g/cc. The density is 
such that the microspheres are readily suspendable in 
the carrier solution used for injection into the affected joint of the host.
In accordance with one embodiment of the invention, 
novel protein compositions have been devised for use as 
radioactivity carriers in therapeutic, diagnostic and 
research applications of nuclear medicine. One particu­
















RA referred to hereinabove and as described in detail 
hereinbelow. These novel compositions, however, are 
adaptable for other radiotherapeutic and diagnostic 
applications in mammals where radioactivity carriers 
may be used including, for example, liver, lung and 
kidney cancer treatment and lung scanning.The compositions of the invention comprise proteins 
which have a predetermined minimum proportion, 
about 6%, of amino acid residues having sulfhydryl- 
containing side chains. The preferred amino acid having 
a sulfhydryl-containing side chain is cysteine 
[HSCH2CH(NH2)]. A major advantage of these com­
positions is that their composition facilitates attachment 
of radioisotopes. Without being bound to any one the­
ory, it is suspected that Re-186 and Re-188 radionu­
clides, in particular, bind to protein compositions pri­
marily at sulfhydryl-containing side chains, as are pres­
ent in cysteine. The sulfhydryl-containing side chain of 
cysteine is not involved in the internal peptide bond, 
and, being located at one end of the amino acid, is avail­
able for the formation of external bonds. A high concen­
tration of available sulfhydryl-containing side chains on 
the composition surface, therefore, is thought to favor labeling efficiency and stability of the bond between the 
radioisotope and the composition.
HSA which, as indicated above, has been previously 
proposed for use in radioactivity carriers for certain 
applications, has about 35 cysteine amino acid residues 
out of a total of about 585 amino acid, residues accord­
ing to Minghetti et al., Molecular Structure o f Human 
Albumin Gene Is Revealed by Nucleotide Sequence within 
^11-22 o f Chromosome 4, J. Biol. Chem., Vol. 261, No. 
15, p. 6753 (1986). Compositions formed substantially 
entirely from HSA, therefore, contain less than about 
6% cysteine. It has been discovered that compositions 
having an increased content of amino acid residues 
having a sulfhydryl-containing side chain, such as cyste­
ine relative to HSA have certain advantages as de­
scribed herein. The compositions of the invention con­
tain at least 6% amino acid residues having a sulfhydryl- 
containing side chain, preferably at least about 10% 
amino acid residues having a sulfhydryl-containing side 
chain, more preferably at least about 25% amino acid 
residues having a sulfhydryl-containing side chain, and 
most preferably at least about 35% amino acid residues 
having a sulfhydryl-containing side chain.
It is also believed that the presence of amino acid 
residues characterized by nitrogen-containing side 
chains may favor labeling efficiency and stability of the 
bond between the radioisotope and the composition. 
The beneficial effect of nitrogen-containing side chains 
is believed to involve interaction among die nitrogen- 
containing side chains, sulfhydryl-containing side 
chains and radionuclides, or at least to otherwise pro­
mote the desired binding between the composition and 
the radionuclides. Compositions of the invention there­
fore preferably, but not necessarily, contain a propor­tion of amino acid residues having nitrogen-containing 
side chains in addition to the amino acid residues having 
sulfhydryl-containing side chains as described above. It 
is also preferred that the compositions of the invention 
contain at least about 10% amino acid residues having 
nitrogen-containing side chains, preferably at least 
about 25% amino acid residues having nitrogen-con­
taining side chains, and more preferably at least about 
35% amino acid residues having nitrogen-containing 
side chains. For these compositions, it is preferred that 
the ratio of amino acid residues having a sulfhydryl-
5 containing side chain to amino acid residues having 
nitrogen-containing side chains be in the range of about 
1:1 to about 1:3.It is believed that the particular amino acid or amino 
acids selected for the amino acid residues having a ni­
trogen-containing side chain is not critical, but the pre­
ferred amino acid is lysine
[NH2(CH2)4CH(NH2)COOH]. One preferred composi­
tion contains a combined cysteine and amino acid hav­
ing a nitrogen-containing side chain content which ap­
proaches 100%. The most preferable of such composi­
tions contains about 50% cysteine and about 50% ly­
sine. Other amino acids having nitrogen-containing side 
chains are substitutable in whole or in part for lysine in 
the compositions. These amino acids include, non- 
exclusively, arginine, asparagine, glutamine, histidine 
and tryptophan.Though protein compositions of the invention are 
preferably formed primarily from cysteine or cysteine 
in combination with an amino acid having a nitrogen- 
containing side chain such as lysine, the compositions 
may also contain certain proportions of other amino 
acids or combinations thereof, depending on the partic­ular application, availability of material, and other fac­tors. The function of amino acids other than those hav­
ing sulfhydryl- or nitrogen-containing side chains, as 
currently understood, is primarily to provide mass to 
the compositions. In addition to lysine and cysteine, 
appropriate amino acids for use in connection with 
these compositions may be selected from the group 
which includes, non-exclusively, alanine, arginine, as­
paragine, aspartic acid, glutamine, glutamic acid, gly­
cine, histidine, isoleucine, leucine, methionine, phenyl­
alanine, proline, serine, threonine, tryptophan, tyrosine 
and valine. As stated above, certain of these amino acids 
have nitrogen-containing side chains and therefore may 
be included in the preferred compositions of the inven­tion. Certain amino acids are appropriate for use in the 
compositions of the invention, irrespective of whether 
they have sulfhydryl-containing or nitrogen-containing 
side chains, so long as they are metabolizable, non-toxic, 
non-antigenic, and otherwise compatible with composi­
tions for use as in vivo radioactivity carriers.
The compositions comprise combinations of amino 
acids which are independent amino acid chains cross- 
linked, for example cysteine or polycysteine cross- 
linked to lysine or polylysine, upon formation of the 
composition. The compositions may also comprise 
polyamino acid chains having different amino acids in 
the same chain, as with a polyamino acid chain of ten 
amino acids, five lysines and five cysteines. Polyamino 
acids used in connection with the invention may be of a 
predetermined sequence.The molecular weight of polyamino acid chains used 
in forming the compositions of the invention is in the 
range of about 1000 to about 50,000 grams per mole, 
preferably in the range of about 10,000 to about 20,000 
grams per mole. Polyamino acid chains for these com­
positions have in the range of about 10 to about 400 
amino acids per chain, preferably in the range of about 
50 to about 200 amino acids per chain, and most prefera­
bly about 100 amino acids per chain. Chains which are 
too long or have too high of a molecular weight are 
difficult to dissolve during the formation of the compo­
sitions. The protein material used to form the composi­
tions may be prepared any of various known or herein­

















Increased radionuclide-to-carrier bond strength and 
stability provided by the above-described compositions 
render the compositions less susceptible than other radi­
oactivity carriers to enzymatic attack in the body and 
therefore less susceptible to in vivo leaching of radioac­
tivity into the host’s system. For example, the strong 
Re-to-sulfhydryl and/or Re-to-amine bond thought to 
be characteristic of Re-radiolabeled cysteine/lysine 
compositions may reduce the tendency of Re to be 
oxidized in vivo to perrhenate. Compositions formed 
primarily from lysine, cysteine and/or other suitable 
amino acids are preferred over HSA due to the forego­
ing advantages and due to immunogenetic and infec­
tion-related concerns with using blood products such as human albumin.
The amino acid or combination of amino acids se­
lected for the compositions are preferably metaboliz­
able, non-toxic, and non-antigenic. The L isomer of the 
selected amino acid is preferred over the D isomer 
because the L conformations are naturally occurring. 
Naturally occurring isomers may be more compatible 
with the host, readily metabolizable, and, being indige­
nous to mammals, more readily approved for use in 
mammals by governmental authorities. It is also pre­
ferred that the amino acid or combination of amino 
acids, when formed and solidified into a composition, be 
sufficiently chemically durable in vivo such that signifi­
cantly harmful amounts of radioactivity are not leached 
from radiolabeled compositions formed therefrom into 
the host’s system during a period of about five half-lives of the attached radioisotope.
The preparation of the preferred protein composi­
tions, when formed into microspheres, can be achieved 
by the emulsification method, the drop-tube method, or 
other suitable methods as is the case with HSA micro- 
spheres. Although the method by which the micro­
spheres are made is not critical to the invention, the 
emulsification method as described herein.
It has been discovered that extensive washing and 
pretreatment of the compositions, both HSA composi­
tions and other protein compositions, significantly im­
prove the chemical durability and overall labelability of 
the compositions. Washing the compositions thor­
oughly with saline and a detergent is thought to remove loosely bound protein molecules. It is most preferred 
that the detergent be a non-ionic detergent, specifically, sodium dodecyl sulfate, but other detergents are suit­
able. Chemical durability in vivo is improved in that 
loosely bound proteins are removed and therefore not 
available to be released, i.e., leached, within the host’s system.
Treatment of the compositions with a reducing agent 
has been found to significantly improve the efficacy of 
the compositions for attachment of radionuclides and 
subsequent use for nuclear medical applications. Pre­
treatment of the compositions in this manner reduces in 
vivo leakage of the radionuclides. Without being bound 
to any one theory, it is suspected that this treatment 
serves to reduce disulfide bonds, formed from sulfhy- dryl groups upon heating of the compositions during 
preparation, back to sulfhydryl groups. This reduction 
is believed to substantially increase the number of avail­
able bonding sites for attachment of radioisotopes to the 
compositions. In particular, it is believed that this pre- 
treatment facilitates the reformation of sulfhydryl 
groups having affinity for the radiolabel to be attached 
(Re(V)). Reducing agents capable of this type of reduc­
tion are well known in the art, including, for example,
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y3-mercaptoethanol (98% 2-hydroxyethyl-mercaptan 
available from Sigma Chemical Co.) and DTT (99% 
DL-dithiothreitol available from Sigma Chemical Co.). 
The reducing agent is provided in a concentration in the range of from about 0.2 to about 10%, preferably in the 
range of from about 0.5 to about 5%, and most prefera­
bly in the range of from about 0.5 to about 2%. The 
compositions are suspended in the reducing agent solu­
tion and heated in a boiling water bath for about 30 to about 90 minutes.
Protein compositions for use in connection with the 
method of the invention can be radiolabeled directly. 
By direct labeling, Re-186 or Re-188 is reduced from 
the VII oxidation state to the V oxidation state and 
bound directly to connecting groups on the composi­
tions. Without being bound to any one theory, radioac­
tive oxo Re(V), reduced from perrhenate, is believed to 
form a stable complex (transfer ligand) which is readily 
attachable to thiol and amine groups on protein mole­
cules. This preferred labeling method and the presumed 
mechanism are further described in FIG. 1. Each milli­
gram of the protein compositions can be labeled with up 
to about 1 to about 4 millicuries Re, but generally is 
labeled with about 50 to about 500 microcuries Re, 
preferably with about 100 to about 400 microcuries Re, 
and most preferably with about 100 to about 300 mi­
crocuries Re. Specifically, a transfer ligand is obtained 
by combining a Re reducing agent such as tin (II) chlo­
ride 99%, a Re stabilizing agent such as citric acid and 
an antioxidant such as gentisic acid in a reaction vial. 
The vial is purged with nitrogen gas and deoxygenized, 
deionized water is added to form a solution having a pH 
of about 3. The desired amount of radioactive perrhe­nate (comprising Re-186 or Re-188), generally about 50 
to about 500 microcuries per milligram of composition 
to be labeled, is transferred into the reaction vial and 
reduced upon heating for about 30 minutes in a boiling 
water bath. The Re(V) citrate complex solution is then 
transferred into a glass tube containing agitated protein 
composition suspension. The glass tube is placed into a 
boiling water bath; stirring and heating are maintained 
for about 1 hour. The Re-labeled compositions are then separated from the aqueous supernatant
Radiolabeling may also be accomplished in accor­dance with the method and mechanism wherein a stable 
Re complex is formed and then attached to the compo­sition as set forth in FIG. 2.
Radiolabeled protein compositions produced as de­
scribed above may be used in connection with the method of the invention for radiation synovectomy 
treatment of RA. In accordance with the method of the 
invention, radiolabeled microspheres prepared as de­
scribed are administered to afflicted joints of a mammal 
by intra-articular injection or other suitable means of 
administration. The dosage for treatment of an afflicted 
joint depends on various factors including the size of the 
joint, the progression of the disease, and the tolerance of 
the patient. The typical dosage is in the range of from 
about 0.5 to about 20 milligrams of microspheres radi­
olabeled with about 50 to about 500 microcuries Re per 
milligram. Upon administration, the microspheres be­
come distributed reasonably uniformly along the syno­
vial membrane and emit beta radiation of sufficient 
strength to fully irradiate the thickness of the membrane 
without imparting significant dosage to more distant 
joint structures. Inasmuch as the thickness of the dis­
eased membrane varies in different joints, the present 
















microspheres for a knee than for a finger joint, for ex­
ample.The following examples illustrate certain preferred 
embodiments of this method and the efficacy of the 
compositions of the invention for radiation therapy, 
including treatment, diagnosis and research, in mam­
mals. The protocol and experimental methods followed 
were approved by the University of Missouri-Columbia 
Animal Care and Use Committee and complied with the 
federal Animal Welfare Act.
EXAMPLE 1
HSA microspheres acceptable for use in connection 
with the method of the invention were produced by 
placing 200-300 ml of cottonseed oil (USP) in a glass 
beaker and stirring at about 500 rpm with a 2\ inch 
propeller-type stirrer. An aqueous solution of 25% 
HSA at ambient temperature was added to the beaker 
using a hypodermic syringe with a 25-gauge needle. 
HSA was added at a volume ratio of 4 ml per liter of oil. 
The oil/HSA mixture was heated to 135° C. and main­
tained at that temperature for about 40 minutes while 
stirring was continued. The oil suspension was cooled 
to room temperature, diluted with heptane, and the 
microspheres were isolated by filtration. After several 
washes with heptane to completely remove the oil, the 
microspheres were dried.
About 15-20 mg of protein microspheres were placed 
with a magnetic stir bar into a 10 ml glass tube for pre­treatment. Five ml of 1-1.5% /3-mercaptoethanol (98% 
2-hydroxyethyl-mercaptan available from Sigma Chem­
ical Co.) and 1 ml of 1% Tween-80 (liquid polyoxoethy- 
lene sorbitan monooleate available from Sigma Chemi­
cal Co.) were added to the tube. 0.5-1.0% DTT (99% 
DL-dithiothreitol available from Sigma Chemical Co.) 
may be substituted for the /3-mercaptoethanol. The 
microsphere suspension was heated in a boiling water 
bath and stirred for 45-60 minutes. The supernatant was removed by centrifugation and the microspheres were 
washed with deionized water and allowed to dry.
Transfer ligand was obtained by placing about 6 mg 
tin (II) chloride 99%, about 55 mg citric acid, about 50 
mg sodium citrate, and about 20 mg gentisic acid in a 5 
ml reaction vial. The vial was purged with nitrogen gas 
and 1.5 ml of previously deoxygenized, deionized water 
was added to form a solution of about pH 3. About 1 to 1.5 ml radioactive perrhenate containing about 5 milli- 
curies of high specific activity Re-186 (about 1 to 3 
curies per milligram) or generator-produced Re-188 
was transferred into the reaction vial containing trans­
fer ligand and reduced upon heating for about 30 min­
utes in a boiling water bath. The Re(V) citrate complex 
solution was promptly transferred into a glass tube con­
taining a micro-stirrer and 1 ml protein microsphere 
suspension in 0.5% Tween-80 containing 15 mg micro- 
spheres. The glass tube was placed into a boiling water 
bath; stirring and heating were maintained for about 1 hour. The Re-labeled microspheres were separated 
from the aqueous supernatant through centrifugation 
and thoroughly washed with deionized water or iso­
tonic saline.
EXAMPLE 2
Polycysteine-polylysine microspheres were pro­
duced by placing 200 ml of mineral oil (USP) in a 500 ml 
glass beaker, stirring with a magnetic stir bar and heat­
ing the oil to about 65° C. A 3 ml solution of polypep­
tide in dichloroacetic acid was added from a 3 ml dis­
9 posable hypodermic syringe using a 25-gauge needle. 
The polypeptide was a 50:50 molar mixture of cysteine 
and lysine. The oil/polypeptide mixture was heated to 
about 120° C. and maintained at that temperature for 
about 60 minutes while stirring was continued. The oil 
suspension was cooled to room temperature and the 
microspheres were isolated by centrifugation. After 
several washes with heptane and acetone to completely 
remove the oil, the microspheres were dried with nitro­
gen gas.
About 15-20 mg of protein microspheres were placed 
with a magnetic stir bar into a 10 ml glass tube for pre- 
treatment. Five ml of 1-1.5% /3-mercaptoethanol (98% 
2-hydroxyethylmercaptan available from Sigma Chemi­
cal Co.) and 1 ml of 1% Tween-80 (liquid polyoxoethy- 
lene sorbitan monooleate available from Sigma Chemi­
cal Co.) were added to the tube. 0.5-1.0% DTT (99% 
/ji-dithiothreitol available from Sigma Chemical Co.) 
may be substituted for the /3-mercaptoethanol. The 
microsphere suspension was heated in a boiling water 
bath and stirred for 45-60 minutes. The supernatant was 
removed by centrifugation and the microspheres were 
washed with deionized water and allowed to dry.
Transfer ligand was obtained by placing about 6 mg 
tin (II) chloride 99%, about 55 mg citric acid, about 50 
mg sodium citrate, and about 20 mg gentisic acid in a 5 
ml reaction vial. The vial was purged with nitrogen gas 
and 1.5 ml of previously deoxygenized, deionized water 
was added to form a solution of about pH 3. About 1 to 
1.5 ml radioactive perrhenate containing about 5 milli- 
curies of high specific, activity Re-186 (about 1 to .3 
curies per milligram) or generator-produced Re-188 
was transferred into the reaction vial containing trans­
fer ligand and reduced upon heating for about 30 min­
utes in a boiling water bath. The Re(V) citrate complex 
solution was promptly transferred into a glass tube con­
taining a micro-stirrer and 1 ml protein microsphere 
suspension in 0.5% Tween-80 containing 15 mg micro- 
spheres. The glass tube was placed into a boiling water 
bath; stirring and heating were maintained for about 1 
hour. The Re-labeled microspheres were separated 
from the aqueous supernatant through centrifugation 
and thoroughly washed with deionized water or iso­
tonic saline.
EXAMPLES 3-6
Microspheres containing about 50% polylysine and 
about 50% polycysteine by mole percent were prepared 
and directly labeled with Re-186 as described above in 
Example 2. Each microsphere had a diameter between 
about 6 and about 80 microns, with about 50% of the 
microspheres having a diameter between about 10 and 
about 40 microns. 1-2 mg microspheres suspended in 
saline solution carrying about 200-400 microcuries 
were injected, using 1 ml tuberculin syringes, into the 
rear knee joint (stifle) of each of four New Zealand 
white rabbits. The radioactivity in the urine of each 
rabbit as measured daily for four days is presented in 
FIG. 3. Each rabbit was sacrificed after four days and 
the data presented in FIGS. 4-5 collected. These data 
reveal that the percent injected dose remaining in the 
stifle after 96 hours was as high as 87%, the percent 
injected dose in the urine averaged about 11%, and the 


















5 mg 50% polylysine and 50% polycysteine micro­
spheres prepared as in Example 2 were placed in saline 
solution at 37° C. The percent radioactivity leached 
after each of four days was determined and is reported 
in FIG. 6. Less than 0.03% of the Re label leached in 96 hours.
EXAMPLE 8
Re-186 labeled HSA microspheres prepared accord­
ing to the method of Example 1, except that they were 
not pretreated with /J-mercaptoethanol or DTT, and 
having a range of diameter from 1 to 50 microns, were 
suspended in isotonic saline solution and injected into 
the rear stifles of each of four New Zealand white rab­
bits using 200 microliter glass syringes. Each rabbit was sacrificed after 24 hours and the data presented in FIG. 
7 collected. In a second in vivo study using micro- 
spheres which had not undergone pretreatment, leakage 
to the urine was significantly higher, about 30%, after 4 days.
EXAMPLE 9
Re-186 labeled HSA microspheres were prepared 
and injected as set forth in Example 8, except that the 
microspheres were suspended in Angiovist instead of isotonic saline solution. Each rabbit was sacrificed after 
24 hours and the data presented in FIG. 7 collected.
EXAMPLE 10
Re-186 labeled HSA microspheres were prepared 
and injected as set forth in Example 9, except that only 
microspheres having diameters of approximately 23 
microns were used. Each rabbit was sacrificed after 24 
hours and the data presented in FIG. 7 collected. The 
mean percent dose of radioactivity distributed at 24 
hours in certain rabbit organs for Examples 8-10 was determined and is presented in FIG. 8.
In view of the above, it will be seen that the several 
objects of the invention are achieved.
Although specific examples of the present invention 
and its application are set forth herein, it is not intended 
that they are exhaustive or limiting of the invention. 
These illustrations and explanations are intended to 
acquaint others skilled in the art with the invention, its 
principles, and its practical application, so that others skilled in the art may adapt and apply the invention in 
its numerous forms, as may be best suited to the require­ments of a particular use.
We claim:
1. A radiolabeled protein composition adapted for radiation therapy or diagnosis of a mammal, comprising 
a beta radiation emitting radioisotope and a protein 
composition comprising at least 10 molar percent amino 
acid residues having a sulfhydryl-containing side chain, 
said composition being sufficiently chemically durable 
in vivo such that significantly harmful amounts of radio­
activity are not leached from the composition into a 
host’s system during a period of about five half-lives of 
the attached radioisotope when the composition is in­
jected into the host’s system.
2. The composition of claim 1, said composition com­
prising at least about 25 molar percent amino acid resi­
dues having a sulfhydryl-containing side chain.
3. The composition of claim 2, said composition com­
prising at least about 35 molar percent amino acid resi­
dues having a sulfhydryl-containing side chain.
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4. The composition of claim 2, said composition fur­
ther comprising at least about 25 molar percent amino 
acid residues having a nitrogen-containing side chain.
5. The composition of claim 1 wherein said beta radi­
ation emitting radioisotope is Re-186, Re-188, or a com­
bination of Re-186 and Re-188.
6. The composition of claim 1 wherein said composi­
tion is a substantially spherical microsphere.
7. A radiolabeled protein microsphere adapted for 
radiation therapy of a mammal comprising a substan­
tially spherical microsphere comprising a protein com­
position and a radioisotope selected from the group 
consisting of Re-186, Re-188, and the combination of 
Re-186 and Re-188, said microsphere having a diameter 
between 10 microns and 30 microns.
8. The microsphere of claim 7 wherein the micro­
sphere comprises at least about 25 molar percent cyste­
ine and at least about 25 molar percent amino acid resi­
dues having a nitrogen-containing side chain.
9. The microsphere of claim 8 wherein said cysteine 
and said amino acid residues having a nitrogen-contain­
ing side chain combine to form about 100% of the mi­
crosphere.
10. A substantially spherical radiolabeled protein 
microsphere adapted for radiation therapy of a mammal 
comprising a substantially spherical microsphere com­
prising at least about 35 molar percent lysine and at least 
about 35 molar percent cysteine and a radioisotope 
selected from the group consisting of Re-186, Re-188, 
and the combination of Re-186 and Re-188.
11. A radiolabeled protein composition adapted for 
radiation therapy or diagnosis of a mammal comprising 
a beta radiation emitting radioisotope and a protein 
composition comprising at least 6 molar percent cyste­
ine, said composition being sufficiently chemically du­
rable in vivo such that significantly harmful amounts of 
radioactivity are not leached from the composition into 
a host’s system during a period of about five half-lives of 
the attached radioisotope when the composition is in­
jected into the host’s system.
12. The composition of claim 11 comprising at least 
about 10 molar percent cysteine and at least about 10 
molar percent amino acid residues having a nitrogen- 
containing side chain.
13. The composition of claim 11 wherein said beta 
radiation emitting radioisotope is Re-186, Re-188, or a 
combination of Re-186 and Re-188.
14. The composition of claim 11 wherein said compo­
sition is a substantially spherical microsphere.
15. The microsphere of claim 7 which is sufficiently 
chemically durable in vivo such that significantly harm­
ful amounts of radioactivity are not leached from the 
composition into a host’s system during a period of 
about five half-lives of the attached radioisotope when 
the composition is injected into the host’s system.
16. A radiolabeled protein composition adapted for 
radiation therapy of a mammal comprising a beta radia­
tion emitting radioisotope and a protein composition 
comprising at least 10 molar percent amino acid resi­
dues having a sulfhydryl-containing side chain, said composition being a solidified protein composition 
which is suspended in a carrier solution for injection 
and administration by distribution of the solidified com­
position to an area of a host to receive radiation therapy.
17. The composition of claim 11, said composition 
comprising at least about 25 molar percent amino acid 
















18. The composition of claim 17 wherein said beta 
radiation emitting radioisotope is Re-186, Re-188, or a 
combination of Re-186 and Re-188.
19. The composition of claim 16 wherein said compo­
sition is a substantially spherical microsphere.
20. The composition of claim 16 having a density 
between about 1.0 and about 1.05 g/cc.
21. The composition of claim 4 wherein the ratio of 
amino acid residues having a sulfhydryl-containing side 
chain to amino acid residues having a nitrogen-contain­
ing side chain is in the range of 1:1 to 3:1.
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22. A radiolabeled protein microsphere adapted for 
radiation therapy of a mammal comprising a spherical 
protein microsphere consisting of 50 molar percent 
polylysine and 50 molar percent polycysteine, said po- 
lylysine and said polycysteine being polyamino acid 
chains consisting of between about 10 and about 400 
amino acid residues per chain, and a radioisotope at­
tached to said microsphere selected from the group 
consisting of Re-186, Re-188, and the combination of 
Re-186 and Re-18 8, said microsphere having a diameter 
between about 6 microns and about 80 microns. * * * * *
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